Eli Lilly's Weight-Loss Drugs Drive Record Q2 Revenue Surge

Strong sales of Mounjaro and Zepbound lead to raised annual outlook and stock gains despite supply challenges.

Eli Lilly's Q2 revenue hit $11.3 billion, surpassing analysts' expectations by over $1 billion.
Mounjaro and Zepbound generated over $4 billion in sales, nearly 40% of total quarterly revenue.
The company raised its annual revenue forecast by $3 billion, expecting up to $46.6 billion.
Eli Lilly's stock has risen 15% since the earnings report, with a year-to-date increase of 53%.
New single-dose vials for Zepbound are being introduced to help meet growing demand.